We're thrilled to welcome EURETINA to Paris! This week, our Principal Investigator, Isabel Audo will deliver a presentation on PRODYGY (Friday at 12:00) and our CMO Kali Stasi presents SparingVision's gene-agnostic approach. We can't wait! 🎉 euretina.org/paris-2025/ #EURETINA25

Day 1 at #EURETINA25 ✅ Fantastic start in Paris! Great discussions on inherited retinal diseases and dry AMD, including presentation of PRODYGY #GeneTherapy #EURETINA25

Day 2 momentum at #EURETINA25 🚀 Another productive day advancing ophthalmology in Paris : from great presentations, to an internal strategy session for the SPVN team, a great team lunch and Fantastic networking opportunities! #GeneTherapy #Ophthalmology #GenomicMedicines

💫4 incredible days in Paris. 🙏Thank you to the amazing organizers and the retinal community - see you next year! #EURETINA25 #GeneTherapy #Ophthalmology #GenomicMedicines

🌟 Dr. Joseph Martel, Principal Investigator of the PRODYGY trial will be presenting at the 58th Retina Society Annual Meeting taking place in Chicago, at 3 :39pm CST in the GENETIC DISEASES, DYSTROPHIES, DEGENERATIONS session. ⚠️Don’t miss the presentation! #SparingVision

🤵‍♀️Our Chief Medical Officer, Kali Stasi, will be participating at the ISGEDR bi-annual meeting on September 12th, in Oslo, Norway during the Panel Discussion “Gene-agnostic therapeutic strategies”- Minisymposium on Therapeutic Innovations in Inherited Retinal Degenerations.

👩‍🔬Mélanie Marie, our Senior Director, Development Sciences is attending at the 59th edition of EUROTOX 2025 , taking place in Athens, Greece, on the 14-17 September. 🌐 PM if you want to meet with Mélanie ! #GeneTherapy #Ophthalmology #GenomicMedicines #EUROTOX2025

Pierre Axel Vinot, our Director, CMC Portfolio Management, will be presenting at Cell and Gene Therapy International, on September 18 in Boston, at 11:45am EST. 👋 If you want to meet Pierre Axel Vinot, get in touch ! #GeneTherapy #Ophthalmology #GenomicMedicines

Spotlight on our lab team ! 🔬 We are proud to highlight our lab team for their role in driving R&D, CMC and quality assurance, contributing to our continued growth. 💙#GeneTherapy #GenomicMedicines #Ophthalmology #SparingVision

📢Our CEO, Stéphane Boissel, CFO, Anjeza Gjino and VP, Investor Relations, Nathalie Delair-Trepo will be participating in the Oppenheimer & Co. Inc. Private Life Sciences Company Showcase, taking place virtually. #GeneTherapy #GenomicMedicines #Oppenheimer #SparingVision

Say hello to Guillaume Hagege, VP, Portfolio & Alliance Management at SparingVision! Guillaume shared his #ophthalmology & #biotech insights into operations and strategy, which drive SparingVisions' mission to deliver real solutions to patients. Link: sparingvision.com/blog/

🌟 Marie Uguen, Chief Regulatory and Quality Officer, is attending the TOPRA Annual Symposium in Berlin from September 29 to October 1, 2025. #SparingVision #TOPRASymposium #RegulatoryAffairs #Innovation

This #BlindnessAwarenessMonth! Join us in spreading awareness for the 350 million people affected by vision loss worldwide. At SparingVision, we harness the potential of #genomic technologies to develop vision-saving treatments. Learn more: sparingvision.com #VisionForAll

🧬 Excited to be in Sevilla! 🇪🇸 🔬 We are delighted to share that today, Hanen Khabou, our Senior Scientist will present the development of SPVN20, a gene therapy for cone reactivation in inherited retinal degeneration during the ESGCT Annual Congress. #ESGCT2024 #GeneTherapy

Today is World Sight Day! Help us spread awareness about eye health for everyone. Share your vision journey with us – glasses wearer, caregiver. Let's empower each other! #WorldSightDay #VisionMatters #EyeHealth

🧬 This week in Sevilla, the SparingVision team presented data on our gene therapy programs SPVN06 and SPVN20 at the ESGCT 2025 Annual Meeting. 🔗 sparingvision.com/sparingvision-… #ESGCT2025 #GeneTherapy #Ophthalmology

Next week, CEO Stéphane Boissel joins the In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications panel at Chardan's 9th Annual #GeneticMedicines Conference in New York. He’ll discuss how SparingVision is advancing agnostic gene therapies for retinal diseases.

🏃‍♀️Two of our colleagues recently took on a race from Paris to Versailles! At SparingVision, we share the same values that drive athletes: determination, teamwork & the will to go further. Bravo Lucile & Benoit 👏 #TeamSpirit #Innovation #Biotech #Running #ParisRace #SparingVision

Meet Alexis, our FP&A Leader! Our October employee #spotlight shows how strategic expertise drives our mission to advance gene-agnostic therapies for patients who need them most. Discover Alexis' story! 👉 sparingvision.com/blog/ #GenomicMedicine

💡Stephane Boissel, President & CEO of SparingVision will be participating in an insightful conference call on the Development of the Next Generation of Innovations in Ophthalmology hosted by ICR Healthcare. 📅: October 30 12:00–1:00PM ET